COMBINATION THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 14, 2022
app pub date -
May 29, 2020
filing date -
May 31, 2019
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The disclosure relates to methods and compositions for the treatment of a B-cell malignancy. Specifically, the disclosure relates to a B-cell malignancy medicament or composition, comprising: (a) an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof that binds to B-cell maturation antigen (BCMA), conjugated to a nucleic acid cross-linking agent; and (b) a proteasome inhibitor.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully